Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 in Children with Recently Diagnosed Type 1 Diabetes
NCT01862120Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2013
- Primary completion
- Jul 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aldesleukin in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Treg response following the induction cure period at Day 5. Started Jun 2013; status: completed.
02
Drugs
aldesleukin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01862120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862120.